Using two YORVIPATH injections to achieve the recommended once daily dosage increases the variability of the total delivered dose, which can cause unintended changes in serum calcium levels, including ...

For less serious hypercalcemia, adjust the dose of YORVIPATH, active vitamin D, and/or calcium supplements. Serious events of hypocalcemia have been observed with PTH products, including YORVIPATH.

Potential safety concerns due to serious adverse reactions reported, including serious hypercalcemia and hypocalcemia, which may pose significant health risks to patients and could lead to ...

Monitor infants breastfed by females treated with YORVIPATH for symptoms of hypercalcemia or hypocalcemia. Consider monitoring serum calcium in the breastfed infant. You are encouraged to report ...

Moderate hypercalcemia is between 12.0 and 13.9 ... A low calcium level (hypocalcemia) is most commonly due to surgical hypoparathyroidism—surgery within the neck causing the parathyroid gland ...

The authors used Ovid Medline to search for human trials on hypercalcemia and furosemide from 1950 to April 2008, and articles related to bisphosphonates and hypercalcemia during the same period.

COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide; developed as TransCon PTH) is now commercially ...